PedAM
Pediatric Disease Annotations & Medicines
| heroin dependence | ||||
| Disease ID | 737 |
|---|---|
| Disease | heroin dependence |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:6) HP:0100710 | Impulsivity | 2 HP:0000716 | Depression | 1 HP:0000739 | Anxiety | 1 HP:0000846 | Hypoadrenalism | 1 HP:0000855 | Insulin resistance | 1 HP:0000083 | Renal insufficiency | 1 |
| Disease ID | 737 |
|---|---|
| Disease | heroin dependence |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:19) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1176744 | 20838391 | 6532 | SLC6A4 | umls:C0019337 | BeFree | The HTR3B rs1176744 gain-of-function Ser129 allele predicted alcohol dependence (P=0.002) and low 5-HTTLPR activity predicted cocaine/heroin dependence (P=0.01). | 0.005819831 | 2011 | HTR3B | 11 | 113932306 | A | C |
| rs1176744 | 20838391 | 3359 | HTR3A | umls:C0019337 | BeFree | In this study, 360 treatment-seeking African American male patients with single and comorbid DSM-IV lifetime diagnoses of alcohol, cocaine and heroin dependence and 187 African American male controls were genotyped for the triallelic 5-HTTLPR functional polymorphism in the 5-HT transporter gene (SLC6A4) and 16 haplotype-tagging single-nucleotide polymorphisms (SNPs) across HTR3B (including the functional rs1176744 Tyr129Ser) and HTR3A, genes encoding 5-HT3 receptors. | 0.000271442 | 2011 | HTR3B | 11 | 113932306 | A | C |
| rs1176744 | 20838391 | 9177 | HTR3B | umls:C0019337 | BeFree | The HTR3B rs1176744 gain-of-function Ser129 allele predicted alcohol dependence (P=0.002) and low 5-HTTLPR activity predicted cocaine/heroin dependence (P=0.01). | 0.002638474 | 2011 | HTR3B | 11 | 113932306 | A | C |
| rs1360780 | 24766650 | 2289 | FKBP5 | umls:C0019337 | BeFree | Fourteen SNPs showed nominally significant association with heroin addiction (p < 0.05), including the African-specific, missense SNP rs5376 (Asn334Ser) in the galanin receptor type 1 gene (GALR1) and the functional FKBP5 intronic SNP rs1360780. | 0.000542884 | 2014 | FKBP5;LOC105375032 | 6 | 35639794 | T | C |
| rs1799971 | 16682632 | 4988 | OPRM1 | umls:C0019337 | BeFree | Mu opioid receptors are critical for heroin dependence, and A118G SNP of the mu opioid receptor gene (OPRM1) has been linked with heroin abuse. | 0.134278137 | 2006 | OPRM1 | 6 | 154039662 | A | G |
| rs1800955 | 18991844 | 1815 | DRD4 | umls:C0019337 | BeFree | The dopamine receptor D4 gene (DRD4) is associated with heroin dependence; one of its polymorphisms is a C/T variation 521 bp upstream to the gene (-521C/T). | 0.011725539 | 2008 | DRD4 | 11 | 636784 | T | C |
| rs2236861 | 18518925 | 4985 | OPRD1 | umls:C0019337 | BeFree | Analysis of a combined effect of OPRM1 and OPRD1 showed that rs510769 and rs2236861 increase the risk of heroin addiction (P = 0.0005). | 0.007915422 | 2008 | OPRD1 | 1 | 28813244 | G | A |
| rs2236861 | 18518925 | 4988 | OPRM1 | umls:C0019337 | BeFree | Analysis of a combined effect of OPRM1 and OPRD1 showed that rs510769 and rs2236861 increase the risk of heroin addiction (P = 0.0005). | 0.134278137 | 2008 | OPRD1 | 1 | 28813244 | G | A |
| rs324029 | 24398431 | 3674 | ITGA2B | umls:C0019337 | BeFree | The GTA haplotype frequency in the block (rs324029, rs6280, rs9825563) was significantly associated with early-onset heroin dependence (p=0.003). | 0.000271442 | 2013 | DRD3 | 3 | 114162776 | A | G |
| rs4680 | 25875614 | 1312 | COMT | umls:C0019337 | BeFree | The Met allele of the functional COMT Val158Met was associated with protection from OD. | 0.007915422 | 2014 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs510769 | 18518925 | 4988 | OPRM1 | umls:C0019337 | BeFree | Analysis of a combined effect of OPRM1 and OPRD1 showed that rs510769 and rs2236861 increase the risk of heroin addiction (P = 0.0005). | 0.134278137 | 2008 | OPRM1 | 6 | 154040884 | C | T |
| rs510769 | 18518925 | 4985 | OPRD1 | umls:C0019337 | BeFree | Analysis of a combined effect of OPRM1 and OPRD1 showed that rs510769 and rs2236861 increase the risk of heroin addiction (P = 0.0005). | 0.007915422 | 2008 | OPRM1 | 6 | 154040884 | C | T |
| rs5326 | 25875614 | 1812 | DRD1 | umls:C0019337 | BeFree | The study results are in accordance with the results of previous studies, including our report of association of DRD1 SNP rs5326 with OD. | 0.002909916 | 2014 | DRD1 | 5 | 175443193 | C | T |
| rs5376 | 24766650 | 2289 | FKBP5 | umls:C0019337 | BeFree | Fourteen SNPs showed nominally significant association with heroin addiction (p < 0.05), including the African-specific, missense SNP rs5376 (Asn334Ser) in the galanin receptor type 1 gene (GALR1) and the functional FKBP5 intronic SNP rs1360780. | 0.000542884 | 2014 | GALR1 | 18 | 77268853 | G | A |
| rs6280 | 24398431 | 3674 | ITGA2B | umls:C0019337 | BeFree | The GTA haplotype frequency in the block (rs324029, rs6280, rs9825563) was significantly associated with early-onset heroin dependence (p=0.003). | 0.000271442 | 2013 | DRD3 | 3 | 114171968 | C | T |
| rs6311 | 24355137 | 4128 | MAOA | umls:C0019337 | BeFree | By MDR (Multifactor Dimensionality Reduction) analyses, the interactive effects between MAOA-LPR and 5-HTTVNTR, and among MAOA-LPR, 5-HTTVNTR and rs6311 were close to the significance level (P=0.05) in predicting the risk of co-morbidity of BPD and heroin dependence relative to normal female controls, with 1000-fold permutation testing P-value<0.06 however >0.05 respectively. | 0.00554839 | 2013 | HTR2A | 13 | 46897343 | C | T |
| rs6311 | 19328219 | 6532 | SLC6A4 | umls:C0019337 | BeFree | This study aimed to investigate whether three serotonergic polymorphisms (HTR2A A-1438G (rs6311), and SCL6A4 5-HTTLPR and STin2 VNTR) were associated with alcohol dependence, and, whether the serotonergic polymorphisms played a similar role in conferring vulnerability in alcohol and heroin dependence. | 0.005819831 | 2009 | HTR2A | 13 | 46897343 | C | T |
| rs6311 | 19328219 | 3356 | HTR2A | umls:C0019337 | BeFree | This study aimed to investigate whether three serotonergic polymorphisms (HTR2A A-1438G (rs6311), and SCL6A4 5-HTTLPR and STin2 VNTR) were associated with alcohol dependence, and, whether the serotonergic polymorphisms played a similar role in conferring vulnerability in alcohol and heroin dependence. | 0.008001298 | 2009 | HTR2A | 13 | 46897343 | C | T |
| rs9825563 | 24398431 | 3674 | ITGA2B | umls:C0019337 | BeFree | The GTA haplotype frequency in the block (rs324029, rs6280, rs9825563) was significantly associated with early-onset heroin dependence (p=0.003). | 0.000271442 | 2013 | DRD3 | 3 | 114181373 | A | G |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:14) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHR | POS | SNPID | REF | ALT | ORI_SNPID | PMID | P_VALUE | P_VALUE_TEXT | OR/BETA | CI95_TEXT | GWAS_INITIAL_SAMPLE_SIZE | SUB_POPULATION | SUPER_POPULATION | GWAS_TRAIT | HPO_ID | HPO_TERM | DO_ID | DO_TERM | MESH_ID | MESH_TERM | EFO_ID | EFO_TERM | DOLITE_TERM | RISK_ALLELE | PUBLICATION_TYPE | AA | GENE_SYMBOL | TYPE | REFGENE |
| 1 | 202602197 | rs10494835 | C | T | rs10494835 | 20520587 | 3.30E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 5 | 160754957 | rs10515827 | C | T | rs10515827 | 20520587 | 3.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 7 | 120096711 | rs917901 | C | T | rs917901 | 20520587 | 6.70E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 7 | 126697650 | rs6467108 | T | C | rs6467108 | 20520587 | 3.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 8 | 26556765 | rs10503794 | C | T | rs10503794 | 20520587 | 6.70E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 8 | 105232783 | rs2511571 | A | G | rs2511571 | 20520587 | 7.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 8 | 105234814 | rs2511576 | T | C | rs2511576 | 20520587 | 7.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 8 | 105247118 | rs1156813 | C | T | rs1156813 | 20520587 | 3.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 9 | 87539664 | rs763623 | G | A | rs763623 | 20520587 | 6.70E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 9 | 101285414 | rs2779577 | C | A | rs2779577 | 20520587 | 3.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 11 | 113029314 | rs1245124 | A | T | rs1245124 | 20520587 | 3.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 11 | 120547912 | rs10502240 | C | T | rs10502240 | 20520587 | 7.00E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 12 | 5048861 | rs10492065 | G | T | rs10492065 | 20520587 | 6.70E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
| 15 | 27423563 | rs1378101 | G | A | rs1378101 | 20520587 | 6.70E-04 | Heroin addiction | NA | NA | 200 European ancestry severe former addicts cases; 125 African American severe former addicts cases; 150 European ancestry controls; 100 African American controls | African American(225) | European(350) | ALL(575) | AFR(225) | EUR(350) | ALL(575) | Heroin addiction | HPOID:0000707 | Abnormality of the nervous system | DOID:9976 | heroin dependence | NA | NA | NA | NA | Drug abuse | NA | Research Support, N.I.H., Extramural |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:8) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0019337 | amphetamine | D000661 | 300-62-9 | heroin dependence | MESH:D006556 | marker/mechanism | 9824469 | ||
| C0019337 | baclofen | D001418 | 1134-47-0 | heroin dependence | MESH:D006556 | therapeutic | 11862373 | ||
| C0019337 | clonidine | D003000 | 4205-90-7 | heroin dependence | MESH:D006556 | therapeutic | 4028630 | ||
| C0019337 | fluoxetine | D005473 | 54910-89-3 | heroin dependence | MESH:D006556 | therapeutic | 19150250 | ||
| C0019337 | methadone | D008691 | 76-99-3 | heroin dependence | MESH:D006556 | therapeutic | 10768702 | ||
| C0019337 | morphine | D009020 | 57-27-2 | heroin dependence | MESH:D006556 | marker/mechanism | 16598705 | ||
| C0019337 | sulpiride | D013469 | 15676-16-1 | heroin dependence | MESH:D006556 | therapeutic | 622221 | ||
| C0019337 | vigabatrin | D020888 | 60643-86-9 | heroin dependence | MESH:D006556 | therapeutic | 14515344 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D006556 | sabril | vigabatrin | 500MG | TABLET;ORAL | Prescription | None | Yes | Yes |
| MESH:D006556 | sabril | vigabatrin | 500MG/PACKET | FOR SOLUTION;ORAL | Prescription | AA | Yes | Yes |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D006556 | 10/26/2013 | sabril | vigabatrin | Refractory complex partial seizures (rCPS) | Approved as adjunctive therapy for pediatric patients 10 years and older with rCPS for whom the potential benefits outweigh the risk of vision loss. Sabril is not a first line agent for rCPS Safety and effectiveness for pediatric patients less than 10 years with refractory rCPS have not been established Pooled data from 3 controlled trials in pediatric patients demonstrated that 6% (10/165) of Sabril patients experienced somnolence compared to 5% (5/104) of placebo patients. In those same studies, 10% (17/165) of Sabril patients experienced fatigue compared to 7% (7/104) of placebo patients; 47% (77/163) of Sabril patients versus 19% (19/102) of placebo patients gained greater than or equal to 7% of baseline body weight Adverse reactions (ARs) in the pediatric population were similar to those reported in adults. Overall, ARs in pediatric patients 10-16 years included increased weight, upper respiratory tract infection, tremor, fatigue, aggression and diplopia Information on weight based dosing, dosing in renal impairment, safety information and clinical trials | Labeling | - | - | B,P | - | Lundbeck LLC | 3/10/2013 | FALSE' |
| MESH:D006556 | 10/26/2013 | sabril | vigabatrin | Refractory complex partial seizures (rCPS) | Approved as adjunctive therapy for pediatric patients 10 years and older with rCPS for whom the potential benefits outweigh the risk of vision loss. Sabril is not a first line agent for rCPS Safety and effectiveness for pediatric patients less than 10 years with refractory rCPS have not been established Pooled data from 3 controlled trials in pediatric patients demonstrated that 6% (10/165) of Sabril patients experienced somnolence compared to 5% (5/104) of placebo patients. In those same studies, 10% (17/165) of Sabril patients experienced fatigue compared to 7% (7/104) of placebo patients; 47% (77/163) of Sabril patients versus 19% (19/102) of placebo patients gained greater than or equal to 7% of baseline body weight Adverse reactions (ARs) in the pediatric population were similar to those reported in adults. Overall, ARs in pediatric patients 10-16 years included increased weight, upper respiratory tract infection, tremor, fatigue, aggression and diplopia Information on weight based dosing, dosing in renal impairment, safety information and clinical trials | Labeling | - | - | B,P | - | Lundbeck LLC | 3/10/2013 | FALSE' |